

A Tutorial on Tackling High Dimensionality in QSP


Jane Knöchel
Scientific Director, InSilicoTrials
Associate Researcher, Potsdam University



QSP's Evolving Role in Industry

Combined with Machine Learning Opens New Frontiers for Precision Medicine

Progression in the number of annual QSP publications/supported FDA submissions[#]



Integrating multi-omics datasets with QSP



Omics

- Large-scale datasets capturing structure and function of biological system


“Patient-specific multi-omics dataset when integrated with QSP models can improve the generation of virtual patient cohorts/digital twin with personalised pharmacokinetics and treatment effect that accurately represent real patients.”¹

[#] Figure redrawn and combined from Cucurull-Sanchez, L. (2024). An industry perspective on current QSP trends in drug development. *Journal of Pharmacokinetics and Pharmacodynamics*, 51(5). And Bai, J. P., Wang, J., Zhang, Y., Wang, L., & Jiang, X. (2023). Quantitative Systems Pharmacology for Rare Disease Drug Development. *Journal of Pharmaceutical Sciences*, 112(9), 2313–2320.
[1] Arulraj, T., Wang, H., Ippolito, A., Zhang, S., Fertig, E. J., & Popel, A. S. (2024). Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology. *Briefings in Bioinformatics*, 25(3).

Understanding inter-individual variability of response


Statistical analysis of clinical data

The data




Data-driven sparse models

Model 1¹



Model 2²



- Identify influencing factors (covariates) e.g. age, bodyweight or others

However, every dataset results in different data-driven sparse model.

Which model to choose for the next analysis?

[1] Hamberg, a-K., Dahl, M.-L., Barban, M., Scordo, M. G., Wadelius, M., Pengo, V., ... Jonsson, E. N. (2007). A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. *Clinical Pharmacology and Therapeutics*, 81(4), 529–538. <https://doi.org/10.1038/sj.clpt.6100084>

[2] The Pitfalls of Warfarin Dosing Using Different Pharmacodynamic Models: A Comparison of Two Different Warfarin Pharmacodynamic Models With Divergent Results. (n.d.), 1–30.

Aim:

Leverage the knowledge in
systems pharmacology models
in statistical analysis


Leveraging the knowledge in system pharmacology models



Knowledge on
covariates included in
system pharmacology
model




Leverage knowledge to
derive theoretically-
justified effective
models including
relevant covariates



Full complexity not
relevant – rather need
to identify important
parts

Method Selection for Reduced Models: Which Approach Yields the Desired Outcome?



No clear guidance exists on which MOR methods suit specific scenarios or how to combine them effectively.

Index Analysis: Understanding what is important

Journal of Pharmacokinetics and Pharmacodynamics
<https://doi.org/10.1007/s10928-017-9561-x>

ORIGINAL PAPER



Understanding and reducing complex systems pharmacology models based on a novel input–response index

Jane Knöchel^{1,3} · Charlotte Kloft² · Wilhelm Huisinga³

Received: 9 April 2017 / Accepted: 6 December 2017
© Springer Science+Business Media, LLC, part of Springer Nature 2017

PLOS COMPUTATIONAL BIOLOGY

RESEARCH ARTICLE

Index analysis: An approach to understand signal transduction with application to the EGFR signalling pathway

Jane Knöchel^{1,2*}, Charlotte Kloft³, Wilhelm Huisinga^{1*}

1 Institute of Mathematics, Universität Potsdam, Potsdam, Germany, **2** Graduate Research Training Program PharmMetX: Pharmacometrics & Computational Disease Modeling, Freie Universität Berlin and Universität Potsdam, Berlin/Potsdam, Germany, **3** Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany

* Current address: AstraZeneca R&D, Mölndal, Sweden
* huisinga@uni-potsdam.de





Index Analysis-guided model order reduction

Index	Type	Purpose	Interpretation
Ir/nir	Input-response	Assess dynamic importance of state	How relevant is a state for the input-output relationship?
Env, Pss	State classification	Classification based on time scale separation	Can we simplify this state by an algebraic equation?
Pneg, Cneg	State classification	Classification of states with negligible impact on the output	Can this state be ignored?


Case Examples

Small example – parallel pathways




Indices reveal appropriate reduction method


Input-response indices



State classification indices of C




Indices guide the model order reduction



orange – dynamical states; light orange – environmental states; white – neglected states

The input-response indices in action



Brown snake venom effect on Fibrinogen



Demonstrates
how the signal
moves through
the network!

Let's combine
this with the
graphical
illustration of the
model!

Understanding Signal Propagation and Key Molecular Players via Input-Response Index



Reduced model:
8 dynamical,
5 environmental
state variables

50 state variables
neglected

output

input

orange – dynamical states; light orange – environmental states; white – neglected states

Theoretical Models for Optimizing Warfarin Therapy

Received: 14 July 2022 | Revised: 18 October 2022 | Accepted: 29 November 2022

DOI: 10.1002/psp4.12903

ARTICLE



Deriving mechanism-based pharmacodynamic models by reducing quantitative systems pharmacology models: An application to warfarin

Undine Falkenhagen^{1,2} | Jane Knöchel¹ | Charlotte Kloft³ | Wilhelm Huisinga¹

Check for updates

ARTICLE

Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR

Undine Falkenhagen^{1,2}, Larisa H. Cavallari³, Julio D. Duarte³, Charlotte Kloft⁴,
Stephan Schmidt⁵ and Wilhelm Huisinga^{2,*}


Warfarin dosing remains challenging due to substantial inter-individual variability, which can lead to unsafe or ineffective therapy with standard dosing. Model-informed precision dosing (MIPD) can help individualize warfarin dosing, requiring the selection of a suitable model. For models developed from clinical data, the dependence on the

Resulting Theoretical Model Size Allows Statistical Analysis of Clinical Data


Modelling Warfarin Therapy (2x60 ODEs)

in vivo

in vitro



Theoretically justified models



Acknowledgement

Financial support:

Graduate Research Training Program PharMetrX



Collaboration partners:

Potsdam University: Institute of Mathematics

Prof. Dr. Wilhelm Huisinga

Dr. Undine Falkenhagen

Johannes Tillil



Freie Universität Berlin: Institute of Pharmacy

Prof. Dr. Charlotte Kloft

